Fluoguide reports widened operating loss in Q2 2026

Danish research firm Fluoguide reported an operating loss of 14.9 million DKK for Q2 2026, compared to a 9.9 million DKK loss in the same period last year. The increased deficit reflects rising operational costs typical of clinical-stage biotech firms, though the impact on long-term liquidity remains to be clarified in future filings.